Monitoring of trough plasma ganciclovir levels and peripheral blood cytomegalovirus (CMV)-specific CD8+ T cells to predict CMV DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 9, 2014, Pages 5602-5605

  Gimeńez, Estela ^a   Solano, Carlos ^a,b   Azanza, José Ramón ^c   Amat, Paula ^a   Navarro, David ^a,b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; GANCICLOVIR; VALGANCICLOVIR; VIRUS DNA; MATRIX PROTEIN; PHOSPHOPROTEIN; PP67 PROTEIN, HUMAN CYTOMEGALOVIRUS;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS DNAEMIA; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOLOGICAL MONITORING; MALE; MIDDLE AGED; NONHUMAN; OBSERVATIONAL STUDY; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS LOAD; ANALOGS AND DERIVATIVES; ANEMIA, APLASTIC; BLOOD; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; MULTIPLE MYELOMA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; STEM CELL TRANSPLANTATION; VIROLOGY;

ADULT; ANEMIA, APLASTIC; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; GANCICLOVIR; HUMANS; INTERFERON-GAMMA; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PHOSPHOPROTEINS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; STEM CELL TRANSPLANTATION; TRANSPLANT RECIPIENTS; VIRAL MATRIX PROTEINS;

EID: 84906086652     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02953-14     Document Type: Article

References (17)

1. Solano C, Navarro D. 2010. Clinical virology of cytomegalovirus infection following hematopoietic transplantation. Future Virol. 5:111-124. http://dx.doi.org/10.2217/fvl.09.64.
2. van der Heiden PL, Kalpoe JS, Barge RM, Willemze R, Kroes AC, Schippers EF. 2006. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant. 37:693-698. http://dx.doi.org/10.1038/sj.bmt.1705311.
3. Einsele H, Reusser P, Bornhäuser M, Kalhs P, Ehninger G, Hebart H, Chalandon Y, Kröger N, Hertenstein B, Rohde F. 2006. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 107: 3002-3008. http://dx.doi.org/10.1182/blood-2005-09-3786.
4. Piketty C, Bardin C, Gilquin J, Mahe V, Kazatchkine MD, Chast F. 1996. Low plasma concentrations achieved with conventional schedules of administration of ganciclovir in patients with AIDS. J. Infect. Dis. 174: 188-190. http://dx.doi.org/10.1093/infdis/174.1.188. (Pubitemid 26255573)
5. Piketty C, Bardin C, Gilquin J, Gairard A, Kazatchkine MD, Chast F. 2000. Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis. Clin. Microbiol. Infect. 6:117-120. http://dx.doi.org/10.1046/j.1469-0691.2000.00014.x. (Pubitemid 34960200)
6. Scott JC, Partovi N, Ensom MH. 2004. Ganciclovir in solid organ transplant recipients: is there a role for clinical pharmacokinetic monitoring? Ther. Drug Monit. 26:68-77. http://dx.doi.org/10.1097/00007691-200402000-00014. (Pubitemid 38140914)
7. - transplant recipients. BMC Infect. Dis. 10:2. http://dx.doi.org/10.1186/1471-2334-10-2.
8. Bedino G, Esposito P, Bosio F, Corradetti V, Valsania T, Rocca C, Pattonieri EF, Gregorini M, Rampino T, Dal Canton A. 2013. The role of therapeutic drug monitoring in the treatment of cytomegalovirus disease in kidney transplantation. Int. Urol. Nephrol. 45:1809-1813. http://dx.doi.org/10. 1007/s11255-012-0293-y.
9. + T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 45:543-549. http://dx.doi.org/10. 1038/bmt.2009.172.
10. + T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: potential implications for the management of active CMV infection. J. Med. Virol. 82: 1208-1215. http://dx.doi.org/10.1002/jmv.21799.
11. Gimeno C, Solano C, Latorre JC, Hernández-Boluda JC, Clari MA, Remigia MJ, Furió S, Calabuig M, Tormo N, Navarro D. 2008. Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. J. Clin. Microbiol. 46:3311-3318. http://dx.doi.org/10.1128/JCM.00797-08.
12. Tormo N, Solano C, Benet I, Nieto J, de la Cámara R, López J, Garcia-Noblejas A, Muñoz-Cobo B, Costa E, Clari MA, Hernández-Boluda JC, Remigia MJ, Navarro D. 2011. Reconstitution of CMV pp65 and IE-1- specific IFN-γ CD8(+) and CD4(+) T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT. Bone Marrow Transplant. 46:1437-1443. http://dx.doi.org/10.1038/bmt.2010.330.
13. Campanero MA, Sadaba B, García-Quetglas E, Azanza JR. 1998. Development and validation of a sensitive method for the determination of ganciclovir in human plasma samples by reversed-phase high-performance liquid chromatography. J. Chromatogr. Biomed. Sci. Appl. 706:311-317. http://dx.doi.org/10.1016/S0378-4347(97)00666-X. (Pubitemid 28130318)
14. Yoshida T1, Takahashi R, Imai K, Uchida H, Arai Y, Oh-ishi, T. 2010. A simple, sensitive determination of ganciclovir in infant plasma by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. Sci. 48:208-211. http://dx.doi.org/10.1093/chromsci/48.3.208.
15. Fletcher C, Sawchuk R, Chinnock B, de Miranda P, Balfour HH, Jr. 1986. Human pharmacokinetics of the antiviral drug DHPG. Clin. Pharmacol. Ther. 40:281-286. http://dx.doi.org/10.1038/clpt.1986.177. (Pubitemid 16017854)
16. Emery VC, Hassan-Walker AF, Burroughs AK, Griffiths PD. 2002. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts. J. Infect. Dis. 185:1723-1728. http://dx.doi.org/10. 1086/340653. (Pubitemid 34615465)
17. Autmizguine J, Théôret Y, Launay E, Duval M, Rousseau C, Tapiéro B, Boivin G, Ovetchkine P. 2011. Low systemic ganciclovir exposure and preemptive treatment failure of cytomegalovirus reactivation in a transplanted child. J. Popul. Ther. Clin. Pharmacol. 18:e257-e260.